Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592555 | 1.00 | F10 (0.57) | F10MAPK1F2ABCB11ST14 | |
| SCHEMBL3447783 | 0.86 | F10 (0.53) | F10F2 | |
| SCHEMBL4592835 | 0.86 | F10 (0.53) | F10F2 | |
| SCHEMBL4592531 | 0.86 | F10 (0.51) | F10MAPK1F2 | |
| SCHEMBL4592458 | 0.86 | F10 (0.51) | F10MAPK1F2 | |
| SCHEMBL4593159 | 0.83 | F10 (0.48) | F10MAPK1F2 | |
| SCHEMBL4592493 | 0.83 | F10 (0.48) | F10MAPK1F2 | |
| SCHEMBL4592524 | 0.83 | F10 (0.48) | F10MAPK1F2 | |
| SCHEMBL4592511 | 0.81 | F10 (0.48) | F10F2 | |
| SCHEMBL4592581 | 0.81 | F10 (0.48) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | claimed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | claimed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |